Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine | Zendy

Russell D. Cohen | Zendy; Márcio Galvão Oliveira | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine

Author(s) -

Russell D. Cohen,

Márcio Galvão Oliveira

Publication year - 2011

Publication title -

drug design development and therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.964

H-Index - 64

ISSN - 1177-8881

DOI - 10.2147/dddt.s5392

Subject(s) - ulcerative colitis , dosing , medicine , pill , extended release , maintenance therapy , pharmacokinetics , food and drug administration , patient compliance , colitis , drug , pharmacology , chemotherapy , disease , emergency medicine

The aminosalicylates (5-ASA; also referred to as mesalamine-based agents) are considered as first-line in the maintenance of remission of mild to moderate ulcerative colitis (UC). Traditionally these agents have required a large pill burden and multiple daily dosing regimens which may account for the low adherence rates, especially in patients in remission. Extended-release mesalamine is the first once daily mesalamine product approved by the Food and Drug Administration for the maintenance of UC remission. This review will examine the pharmacokinetics, dosing, efficacy, and safety data of extended-release mesalamine, and discuss the potential role of improving medication compliance and decreasing costs in UC maintenance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research